OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
High on-treatment platelet reactivity (HOPR) is associated with increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). We sought to investigate the efficacy and safety of 1-month intensified antiplatelet therapies in post-PCI patients with HOPR.
Epistemonikos ID: f81cf133ec042582233643a992ed78a3207582ca
First added on: May 11, 2024